Opendata, web and dolomites

iLIVE SIGNED

Living well, dying well. A research programme to support living until the end

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iLIVE project word cloud

Explore the words cloud of the iLIVE project. It provides you a very rough idea of what is the project "iLIVE" about.

membership    guidelines    care    perhaps    every    training    tool    strategic    expectations    realise    religious    public    six    innovative    appropriate    21st    caregivers    issue    months    life    digital    policy    disease    contexts    core    health    settings    perform    optimize    decrease    2000    patients    socio    cohort    interventions    strategy    person    trials    clinical    country    die    groups    prospective    initiated    worldwide    pain    informed    personal    societal    symptoms    effectiveness    burdens    hold    suffering    genders    century    volunteer    ages    national    direct    bodies    decision    illness    pressing    first    reducing    million    diagnoses    preferences    people    families    ilive    isolation    linking    distress    adaptive    hospital    relieve    collaborative    embeds    dying    social    alone    international    expectancy    chronic    tools    significantly    extensive    medication    economic    outcome    influential    posts   

Project "iLIVE" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 4˙108˙817 €
 EC max contribution 4˙017˙817 € (98%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 655˙750.00
2    THE UNIVERSITY OF LIVERPOOL UK (LIVERPOOL) participant 428˙500.00
3    UNIVERZITETNA KLINIKA ZA PLJUCNE BOLEZNI IN ALERGIJO GOLNIK SI (GOLNIK) participant 418˙950.00
4    FUNDACION CUDECA ES (ARROYO MIEL) participant 413˙500.00
5    LUNDS UNIVERSITET SE (LUND) participant 402˙250.00
6    UNIVERSITAET BERN CH (BERN) participant 394˙750.00
7    HELSE BERGEN HF*HAUKELAND UNIVERSITY HOSPITAL NO (BERGEN) participant 344˙750.00
8    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 229˙750.00
9    PALLIUM LATINOAMERICA ASOCIACION CIVIL AR (BUENOS AIRES) participant 227˙250.00
10    LANDSPITALI UNIVERSITY HOSPITAL IS (REYKJAVIK) participant 219˙750.00
11    MEDIZINISCHE UNIVERSITAET WIEN AT (WIEN) participant 176˙742.00
12    STICHTING UNIVERSITEIT VOOR HUMANISTIEK NL (UTRECHT) participant 105˙875.00
13    AROHANUI HOSPICE SERVICE TRUST NZ (PALMERSTON NORTH) participant 0.00
14    St.Vincent's Hospital (Melbourne) Ltd AU (MELBOURNE) participant 0.00

Map

 Project objective

Every year around 4 million people die in the EU as a result of chronic disease and illness. Many will die in pain or distress, die alone, and die without appropriate health or social care. How we care for the dying is perhaps the most pressing personal, social and public health issue of the 21st century.

To address this problem, the iLIVE project will demonstrate the effectiveness and cost-effectiveness of two innovative interventions in end-of-life care. Its objective is to develop and evaluate: • a digital clinical tool to optimize medication management to relieve symptoms that occur at the end of life • an international volunteer programme to support patients and their families, dying in the hospital

iLIVE will also provide in-depth understanding of the concerns, expectations and preferences of dying patients and their caregivers and deliver the first Core Outcome Set for care of the dying.

To realise this, we will perform a 10-country prospective cohort study of 2000 patients with a life expectancy of six months or less, across different settings, diagnoses, ages, genders, socio-economic and religious groups. The cohort study embeds two controlled clinical trials.

iLIVE is initiated by the ‘International Collaborative for Best Care of the Dying Person’, with worldwide membership. All iLIVE partners have direct access to care of dying patients and hold strategic posts in highly influential national and international bodies linking to policy and strategic decision making. iLIVE will deliver a set of tools and training programmes that are adaptive to different working contexts and informed by dying patients and their caregivers. With an extensive dissemination strategy, iLIVE will significantly contribute to reducing the suffering and isolation of dying patients and their families, improve clinical guidelines, and decrease societal and economic burdens around care for the dying in Europe and beyond.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ILIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ILIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

ISOLDA (2020)

Improved Vaccination Strategies for Older Adults

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More